EMA accepts Biogen, AbbVie's MS application; Shire teams up for rare disease R&D;

@FierceBiotech: EuroBiotech Report: Billionaires drive Malin to €330M IPO, Push for EU JOBS Act, RNAi stock jumps on PhIIa data. Read more | Follow @FierceBiotech

@JohnCFierce: ICYMI: Not giving up day job, but interviewing @Asthika from Bloomberg Intelligence on biotech market was fun. Watch | Follow @JohnCFierce

@DamianFierce: Early contender for next year's #FierceMadness: $LLY and Boehringer say Jardiance + metformin = Synjardy. | Follow @DamianFierce

> The European Medicines Agency has accepted Biogen ($BIIB) and AbbVie's ($ABBV) application for daclizumab, a once-a-month treatment for multiple sclerosis. More

> Novo Nordisk ($NVO) is launching Novoeight, a new factor-replacement therapy for hemophilia A. News

> Shire ($SHPG) is pairing up with the Cincinnati Children's Hospital Medical Center to discover and develop new treatments for rare diseases in a three-year partnership. Release

Medical Device News

@FierceMedDev: Olympus releases updated endoscope cleaning instructions amid pushback. Story | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: Dr. Reddy's shopping for deals up to $1B as it expands in injectable meds. Report | Follow @EmilyWFierce

> Google, J&J partner to advance surgical robotics. More

> Premier CEO says hospitals must integrate their supply chain to track spending on medical devices. Article

Pharma News

@FiercePharma: Jaguar Animal Health eyes a second run at IPO. Story from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: IPCA says FDA bans will have little sales impact. Didn't Wockhardt make that claim before its profits sank? FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Hey, European countries--join forces to bring down drug prices, WHO suggests. Article | Follow @CarlyHFierce

> Genentech project to add 100 jobs. News

> Orexigen's Mysimba catches up to Saxenda at EMA finish line. Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.